Diplomat Pharmacy was Downgraded to a Hold Rating at Avondale

By Austin Angelo

Avondale analyst Greg Bolan downgraded Diplomat Pharmacy (NYSE: DPLO) to Hold today. The company’s shares closed yesterday at $22.38, close to its 52-week low of $22.06.

According to TipRanks.com, Bolan is a 4-star analyst with an average return of 9.3% and a 60.5% success rate. Bolan covers the Healthcare sector, focusing on stocks such as Albany Molecular Research, Quintiles Transnational, and Charles River Labs .

Currently, the analyst consensus on Diplomat Pharmacy is Hold and the average price target is $23.50, representing a 5.0% upside.

In a report released today, Mizuho Securities also reiterated a Hold rating on the stock with a $17 price target.

The company has a one year high of $38.94 and a one year low of $22.06. Currently, Diplomat Pharmacy has an average volume of 753.8K.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. Last month, Philip Hagerman, the Chairman & CEO of DPLO bought 3,347 shares.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It focuses on improving the lives of patients with complex chronic diseases. The company offers a broad range of innovative solutions to address the dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost specialty drugs. Diplomat Pharmacy was founded by Dale Hagerman and Phil Hagerman in 1975 and is headquartered in Flint, MI.